Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 3 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 4 AUG 13 CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5 AUG 20 CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7 AUG 27 USPATOLD now available on STN
NEWS 8 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10 SEP 13 FORIS renamed to SOFIS
NEWS 11 SEP 13 INPADOCDB enhanced with monthly SDI frequency
NEWS 12 SEP 17 CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13 SEP 17 CAplus coverage extended to include traditional medicine patents
NEWS 14 SEP 24 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15 OCT 02 CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16 OCT 19 BEILSTEIN updated with new compounds
NEWS 17 NOV 15 Derwent Indian patent publication number format enhanced
NEWS 18 NOV 19 WPIX enhanced with XML display format
NEWS 19 NOV 30 ICSD reloaded with enhancements
NEWS 20 DEC 04 LINPADOCDB now available on STN
NEWS 21 DEC 14 BEILSTEIN pricing structure to change
NEWS 22 DEC 17 USPATOLD added to additional database clusters
NEWS 23 DEC 17 IMSDRUGCONF removed from database clusters and STN
NEWS 24 DEC 17 DGENE now includes more than 10 million sequences
NEWS 25 DEC 17 TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26 DEC 17 MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27 DEC 17 CA/CAplus enhanced with new custom IPC display formats
NEWS 28 DEC 17 STN Viewer enhanced with full-text patent content from USPATOLD

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:21:21 ON 26 DEC 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 13:22:18 ON 26 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 DEC 2007 HIGHEST RN 959463-53-7
DICTIONARY FILE UPDATES: 25 DEC 2007 HIGHEST RN 959463-53-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10526960\10526960a.str





chain nodes :
7 16 17 18 19 20 21 22 23 24 27 28
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
chain bonds :
1-24 2-28 3-16 5-27 6-7 7-8 11-21 16-17 17-18 18-19 19-20 21-22 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
1-24 2-28 3-16 5-27 6-7 7-8 8-9 8-13 9-10 10-11 11-12 11-21 12-13
16-17 17-18 18-19 19-20 21-22 21-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:N,CH

G2:X,O,CH3,H

G3:H,X

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:CLASS
22:CLASS 23:CLASS 24:CLASS 27:CLASS 28:CLASS

```
L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 N,CH

G2 X,O,Me,H

G3 H,X

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 13:23:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1157 TO ITERATE

100.0% PROCESSED     1157 ITERATIONS                                  5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        21100 TO    25180
PROJECTED ANSWERS:               5 TO      234

L2            5 SEA SSS SAM L1

=> d scan

L2   5 ANSWERS   REGISTRY  COPYRIGHT 2007 ACS on STN
IN   Pyrazinecarboxamide, 5-[2-fluoro-4-[[(3-methylbutyl)amino]methyl]phenoxy]-
     (9CI)
MF   C17 H21 F N4 O2
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[3-(1-methylethoxy)propyl]amino]methyl]phenoxy]-
MF C20 H27 N3 O4
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Pyridinecarboxamide, 5-[2-methyl-4-[[(3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI)
MF C19 H25 N3 O2 . C H4 O3 S

CM 1



CM 2

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full
FULL SEARCH INITIATED 13:23:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 23372 TO ITERATE

100.0% PROCESSED 23372 ITERATIONS 95 ANSWERS
SEARCH TIME: 00.00.01

L3 95 SEA SSS FUL L1

=> d scan

L3 95 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[(3-methoxypropyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI)
MF C18 H23 N3 O4 . C H4 O3 S

CM 1



CM 2

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 173.00 173.42

FILE 'CAPLUS' ENTERED AT 13:23:54 ON 26 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Dec 2007 VOL 147 ISS 26
FILE LAST UPDATED: 25 Dec 2007 (20071225/ED)

=> s l3
L4 3 L3

=> d l4 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:880769 CAPLUS
DOCUMENT NUMBER: 145:306599
TITLE: The μ-opioid receptor subtype is required for the anorectic effect of an opioid receptor antagonist
AUTHOR(S): Zhang, Jiaping; Frassetto, Andrea; Huang, Ruey-Ruey C.; Lao, Julie Z.; Pasternak, Alexander; Wang, Sheng-ping; Metzger, Joseph M.; Strack, Alison M.; Fong, Tung M.; Chen, Richard Z.
CORPORATE SOURCE: Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: European Journal of Pharmacology (2006), 545(2-3), 147-152
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A diaryl ether derivative, 6-(4-{[(3-methylbutyl)amino]methyl}phenoxy)nicotinamide, was prepared and investigated for its biochem. properties at cloned opioid receptors and its pharmacol. effects on animal feeding. The compound displaced [3H]DAMGO binding of human μ-opioid receptor, [3H]U-69593 of human κ-opioid receptor, and [3H]DPDPE of human δ-opioid receptor with IC50 values of 0.5±0.2 nM, 1.4±0.2 nM, and 71±15 nM, resp. The compound also potently inhibited [3H]DAMGO binding of cloned mouse and rat μ-opioid receptors (IC50 ≈ 1 nM), and acted as a competitive antagonist in a cAMP functional assay using cultured cells expressing human or mouse μ-opioid receptors. Following a single oral administration in diet-induced obese mice (at 10 or 50 mg/kg) or rats (at 1, 3, or 10 mg/kg), the compound caused a dose-dependent suppression of acute food intake and body weight gain in both species. Importantly, the anorectic efficacy of the compound was mostly diminished in mice deficient in the μ-opioid receptor. Our results suggest an important role for the μ-opioid receptor subtype in animal feeding regulation and support the development of μ-selective antagonists as potential agents for treating human obesity.
IT 676494-92-1, 6-(4-[[(3-Methylbutyl)amino]methyl]phenoxy)nicotinami

de
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(μ-opioid receptor subtype is required for anorectic effect of an opioid receptor antagonist)

RN 676494-92-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:638874 CAPLUS

DOCUMENT NUMBER: 143:153386

TITLE: A preparation of di(hetero)aryl ethers, useful as opioid receptor antagonists

INVENTOR(S): De La Torre, Marta Garcia; Diaz Buezo, Nuria; Jadhav, Prabhakar Kondaji; Mitch, Charles Howard; Pedregal-Tercero, Concepcion

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 67 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005066164	A1	20050721	WO 2004-US39766	20041215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004312312	A1	20050721	AU 2004-312312	20041215
CA 2549089	A1	20050721	CA 2004-2549089	20041215
EP 1699783	A1	20060913	EP 2004-812312	20041215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1894240	A	20070110	CN 2004-80037824	20041215
BR 2004017714	A	20070320	BR 2004-17714	20041215
JP 2007516284	T	20070621	JP 2006-547016	20041215
US 2007112036	A1	20070517	US 2006-581178	20060531
IN 2006DN03118	A	20070824	IN 2006-DN3118	20060531
MX 2006PA07198	A	20060904	MX 2006-PA7198	20060622

PRIORITY APPLN. INFO.: EP 2003-380303 A 20031222
US 2004-539748P P 20040128
WO 2004-US39766 W 20041215

OTHER SOURCE(S): CASREACT 143:153386; MARPAT 143:153386

GI



I



II

AB The invention relates to a preparation of di(hetero)aryl ethers, useful as opioid receptor antagonists. The invention compds. are useful for the treatment, prevention or amelioration of obesity and related diseases. For instance, phenoxynicotinamide derivative I [GTP-γ-S binding assay, Ki (nM): μ - 43.43, κ - 117.09, δ - 269.06] was prepared via addition of hydroxylamine to phenoxynicotinonitrile derivative II with a yield of 63%.

IT 676494-92-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of di(hetero)aryl ethers useful as opioid receptor antagonists)

RN 676494-92-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:267241 CAPLUS
DOCUMENT NUMBER: 140:303538
TITLE: Preparation of [[(aminoalkyl)aryl]oxy]nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions
INVENTOR(S): Blanco-Pillado, Maria-Jesus; Chappell, Mark Donald; Garcia De la Torre, Marta; Diaz Buezo, Nuria; Fritz, James Erwin; Holloway, William Glen; Matt, James Edward, Jr.; Mitch, Charles Howard; Pedregal-Tercero, Concepcion; Quimby, Steven James; Siegel, Miles

Goodman; Smith, Dana Rae; Stucky, Russell Dean; Takeuchi, Kumiko; Thomas, Elizabeth Marie; Wolfe, Chad Nolan

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 559 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026305	A1	20040401	WO 2003-US26300	20030917
WO 2004026305	A9	20040513		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499690	A1	20040401	CA 2003-2499690	20030917
AU 2003269980	A1	20040408	AU 2003-269980	20030917
BR 2003014308	A	20050705	BR 2003-14308	20030917
EP 1562595	A1	20050817	EP 2003-751877	20030917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1681498	A	20051012	CN 2003-822241	20030917
JP 2006511474	T	20060406	JP 2004-537682	20030917
US 2006217372	A1	20060928	US 2005-526960	20050303
MX 2005PA03093	A	20050713	MX 2005-PA3093	20050318
IN 2005KN00457	A	20060303	IN 2005-KN457	20050318
NO 2005001871	A	20050418	NO 2005-1871	20050418

PRIORITY APPLN. INFO.: US 2002-412158P P 20020919
WO 2003-US26300 W 20030917

OTHER SOURCE(S): MARPAT 140:303538

GI



I



II

AB Title diaryl ethers I [wherein X1-X10 = independently C, CH, or N; provided that each of rings A or B has no more than 2 N atoms; E = O or NH; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, (aryl)heterocyclyl, (cyclo)alkylheterocyclyl, (cyclo)alkanoylalkyl, aroylalkyl, aryloxyalkyl, benzhydryl, bicyclyl(alkyl), benzoyl(alkyl), alkoxyalkyl, alkoxycarbonyl, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, cycloalkylalkyl, carboxyalkyl, carbamoylalkyl, etc.; R3 and R3' = independently H, alkyl, alkenyl, alkynyl, (alkyl)aryl, or alkylcycloalkyl; R4 and R5 = independently H, (halo)alkyl, alkenyl, alkynyl, alkoxy(halo)alkyl, thioalkyl, halo, aryl(alkyl), alkanoyl, alkoxycarbonyl, aminoalkyl, cycloalkylalkyl, etc.; R6 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, alkanoyl, OH, alkoxy, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, aryl(alkyl), carbamoyl(alkyl), etc.; m = 1-3; n = 0-3; p = 0-3; or pharmaceutically acceptable salts, solvates, enantiomers, racemates, diastereomers, or mixts. thereof] were prepared as μ-, κ-, and δ-opioid receptor antagonists. For example, reductive amination of 6-(2-fluoro-4-formylphenoxy)nicotinamide and 3-methylbutylamine provided II (99%). The latter inhibited ex vivo binding of [3H]-diprenorphine in rat striatum/nucleus accumbens by >65% at a concentration of 7 mg/kg. In an acute feeding rat obesity assay, II suppressed opioid receptors at a dose of 0.3 μg/kg. In addition, diet-induced obese rats achieved an energy balance (caloric intake minus utilization) of -81 kcal/kg/day upon administration of 0.3 mg/kg p.o. of II in an indirect calorimetry assay. Thus, I and their pharmaceutical compns. are useful for the treatment, prevention, or amelioration of obesity and related diseases.

IT 676496-49-4P, 5-[4-[(3-Methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide 676497-19-1P, 6-[2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy]nicotinamide 676497-85-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)

RN 676496-49-4 CAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676497-19-1 CAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[(4-methylpentyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676497-85-1 CAPLUS
CN Carbamic acid, [[4-[[5-(aminocarbonyl)-2-pyridinyl]oxy]-3-chlorophenyl]methyl](3,3-dimethylbutyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 676494-38-5P, 6-[2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy]nicotinamide 676494-39-6P, 6-[2-Fluoro-4-[[(3-methylbutyl)amino]methyl]phenoxy]nicotinamide 676501-07-8P, 5-[4-[[(4,4-Dimethylpentyl)amino]methyl]-2-fluorophenoxy]pyridine-2-carboxamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(opioid receptor antagonist; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)

RN 676494-38-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methyl-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-39-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676501-07-8 CAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[(4,4-dimethylpentyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)



IT 676494-40-9P, 6-[2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy]nicotinamide 676494-41-0P, 6-[2-Ethoxy-4-[(3-methylbutylamino)methyl]phenoxy]nicotinamide 676494-49-8P, 6-[4-[(3,3-Dimethylbutylamino)methyl]-2-methylphenoxy]nicotinamide 676494-51-2P, 6-[4-[(Butylamino)methyl]-2-methylphenoxy]nicotinamide 676494-52-3P, 6-[2-Methyl-4-[[methyl(3-methylbutyl)amino]methyl]phenoxy]nicotinamide 676494-82-9P, 6-[4-[(3-Phenylpropylamino)methyl]phenoxy]nicotinamide 676494-83-0P, 6-[4-[(3,3-Diphenylpropylamino)methyl]phenoxy]nicotinamide 676494-84-1P, 6-[4-[(3,3-Dimethylbutylamino)methyl]phenoxy]nicotinamide 676494-92-1P, 6-[4-[(3-Methylbutylamino)methyl]phenoxy]nicotinamide 676494-95-4P, 6-[4-[(6-Hydroxyhexylamino)methyl]phenoxy]nicotinamide 676494-97-6P, 6-[4-[(Decylamino)methyl]phenoxy]nicotinamide 676495-03-7P, 6-[4-[[[3-(2-Methylpiperidin-1-yl)propyl]amino]methyl]phenoxy]nicotinamide 676495-06-0P, 6-[4-[(Pentylamino)methyl]phenoxy]nicotinamide 676495-11-7P, 4-[4-[(Pentylamino)methyl]phenoxy]benzamide 676495-42-4P, 6-[4-[(3-Methylbutylamino)methyl]-2-ethoxyphenoxy]nicotinamide methanesulfonate 676495-43-5P, 6-[4-[(Butylamino)methyl]-2-ethoxyphenoxy]nicotinamide 676496-50-7P, 5-[4-[(3-Methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide methanesulfonate 676496-52-9P, 5-[2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide methanesulfonate 676496-55-2P, 5-[2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide methanesulfonate 676496-80-3P, 5-[2-Fluoro-4-[(3-methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide methanesulfonate 676496-84-7P, 5-[2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy]pyrazine-2-carboxamide methanesulfonate 676496-88-1P, 5-[2-Fluoro-4-[(pentylamino)methyl]phenoxy]pyridine-2-carboxamide 676496-93-8P, 5-[2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide 676496-96-1P, 5-[2-Chloro-4-[(pentylamino)methyl]phenoxy]pyridine-2-carboxamide 676496-99-4P, 6-[2-Methoxy-4-[(3-methylbutylamino)methyl]phenoxy]nicotinamide 676497-06-6P, 6-[2-Methoxy-4-[(pentylamino)methyl]phenoxy]nicotinamide 676497-10-2P, 6-[4-[(3,3-Dimethylbutylamino)methyl]-2-methoxyphenoxy]nicotinamide 676497-12-4P, 6-[4-[(Butylamino)methyl]-2-methoxyphenoxy]nicotinamide 676497-18-0P, 6-[4-[(Hexylamino)methyl]-2-methoxyphenoxy]nicotinamide 676497-20-4P, 6-[2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy]nicotinamide methanesulfonate 676497-24-8P, 5-[4-[(3,3-Dimethylbutylamino)methyl]-2-methylphenoxy]pyrazine-2-carboxamide 676497-25-9P, 5-[4-[(3-Methylbutylamino)methyl]phenoxy]pyrazine-2-carboxamide 676497-29-3P, 5-[4-[(3,3-Dimethylbutylamino)methyl]phenoxy]pyrazine-2-carboxamide 676497-67-9P, 6-[2-Fluoro-4-[[(3-methylbutyl)(pentyl)amino]methyl]phenoxy]nicotinamide 676497-68-0P, 6-[2-Fluoro-4-[[N-(3-methylbutyl)-N-propylamino]methyl]phenoxy]nicotinamide 676497-69-1P, 6-[4-[[Bis(3-methylbutyl)amino]methyl]-2-fluorophenoxy]nicotinamide 676497-86-2P, 6-[2-Chloro-4-[(3,3-dimethylbutylamino)methyl]phenoxy]nicotinamide 676498-03-6P,

4-[2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy]benzamide
676498-08-1P, 4-[3-Chloro-4-[(3-methylbutylamino)methyl]phenoxy]be
nzamide 676498-13-8P, 4-[2-Ethoxy-4-[(3-
methylbutylamino)methyl]phenoxy]benzamide 676499-89-1P,
6-[4-[[(3-Methylbutyl)(cyclopropylmethyl)amino]methyl]-2-
fluorophenoxy]nicotinamide 676499-90-4P, 6-[4-[[(3-
Methylbutyl)(cyclohexylmethyl)amino]methyl]-2-fluorophenoxy]nicotinamide
676500-01-9P, 6-[2-Fluoro-4-[(propylamino)methyl]phenoxy]nicotinam
ide 676500-02-0P, 6-[2-Fluoro-4-[(hexylamino)methyl]phenoxy]nico
tinamide 676500-23-5P, 4-[2-Chloro-4-[(3,3-
dimethylbutylamino)methyl]phenoxy]benzamide 676500-24-6P,
4-[2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy]benzamide
676500-25-7P, 6-[4-[[(3-Methylbutyl)amino]methyl]phenoxy]nicotinam
ide hydrochloride 676500-26-8P, 4-[2-Chloro-4-
[(pentylamino)methyl]phenoxy]benzamide 676500-38-2P,
6-[2,3-Difluoro-4-[(pentylamino)methyl]phenoxy]nicotinamide
676500-42-8P, 6-[4-[(3,3-Dimethylbutylamino)methyl]-2-fluoro-6-
methoxyphenoxy]nicotinamide 676500-45-1P, 6-[4-[(3,3-
Dimethylbutylamino)methyl]-2,6-difluorophenoxy]nicotinamide
676500-48-4P, 6-[2,6-Difluoro-4-[(3-methylbutylamino)methyl]phenox
y]nicotinamide 676500-49-5P, 6-[2,3,6-Trifluoro-4-[(3-
methylbutylamino)methyl]phenoxy]nicotinamide 676500-65-5P,
5-[2-Methoxy-4-[(pentylamino)methyl]phenoxy]pyrazine-2-carboxamide
676500-73-5P, 6-[2-Methoxy-4-[(propylamino)methyl]phenoxy]nicotina
mide methanesulfonate 676500-81-5P, 6-[4-[(Heptylamino)methyl]-2-
methoxyphenoxy]nicotinamide methanesulfonate 676500-85-9P,
6-[2-Methoxy-4-[(3-methoxypropylamino)methyl]phenoxy]nicotinamide
methanesulfonate 676500-87-1P, 6-[4-[(3-
Ethoxypropylamino)methyl]-2-methoxyphenoxy]nicotinamide methanesulfonate
676500-89-3P, 6-[4-[(3-Isopropoxypropylamino)methyl]-2-
methoxyphenoxy]nicotinamide methanesulfonate 676500-93-9P,
6-[4-[(3-Ethylpentylamino)methyl]-2-methoxyphenoxy]nicotinamide
methanesulfonate 676500-98-4P, 6-[2-Methoxy-4-[[[3-(morpholin-4-
yl)propyl]amino]methyl]phenoxy]nicotinamide methanesulfonate
676500-99-5P, 5-[4-[(3,3-Dimethylbutylamino)methyl]-2-
fluorophenoxy]pyrazine-2-carboxamide 676501-05-6P,
5-[2-Fluoro-4-[(4-methylpentylamino)methyl]phenoxy]pyridine-2-carboxamide
676501-06-7P, 5-[4-[(3,3-Dimethylbutylamino)methyl]-2-
fluorophenoxy]pyridine-2-carboxamide 676501-08-9P,
5-[4-[(3-Ethylpentylamino)methyl]-2-fluorophenoxy]pyridine-2-carboxamide
676501-12-5P, 5-[2-Fluoro-4-[(pentylamino)methyl]phenoxy]pyrazine-
2-carboxamide 676501-13-6P, 5-[4-[(4,4-
Dimethylpentylamino)methyl]-2-fluorophenoxy]pyrazine-2-carboxamide
676501-14-7P, 5-[4-[(3-Ethylpentylamino)methyl]-2-
fluorophenoxy]pyrazine-2-carboxamide 676501-19-2P,
5-[2-Fluoro-4-[(hexylamino)methyl]phenoxy]pyrazine-2-carboxamide
676501-21-6P, 5-[2-Fluoro-4-[(3-isopropoxypropylamino)methyl]pheno
xy]pyrazine-2-carboxamide 676501-32-9P, 5-[2-Methoxy-4-[(3-
methylbutylamino)methyl]phenoxy]pyrazine-2-carboxamide
676501-33-0P, 5-[2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy]
pyrazine-2-carboxamide 676501-34-1P, 5-[4-[(3,3-
Dimethylbutylamino)methyl]-2-methoxyphenoxy]pyrazine-2-carboxamide
676501-35-2P, 5-[4-[(4,4-Dimethylpentylamino)methyl]-2-
methoxyphenoxy]pyrazine-2-carboxamide 676501-36-3P,
5-[4-[(3-Ethylpentylamino)methyl]-2-methoxyphenoxy]pyrazine-2-carboxamide
676501-39-6P, 5-[2-Methoxy-4-[(3-methoxypropylamino)methyl]phenoxy
]pyrazine-2-carboxamide 676501-81-8P, 5-[2-Fluoro-4-[(3-
methylbutylamino)methyl]phenoxy]pyrazine-2-carboxamide
676501-82-9P, 6-[2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy]ni
cotinamide methanesulfonate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(opioid receptor antagonist; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)

RN 676494-40-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-chloro-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-41-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-ethoxy-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-49-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(3,3-dimethylbutyl)amino]methyl]-2-methylphenoxy]- (CA INDEX NAME)



RN 676494-51-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(butylamino)methyl]-2-methylphenoxy]- (CA INDEX NAME)



RN 676494-52-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methyl-4-[[methyl(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-82-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(3-phenylpropyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-83-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(3,3-diphenylpropyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-84-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(3,3-dimethylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-92-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-95-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(6-hydroxyhexyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-97-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(decylamino)methyl]phenoxy]- (CA INDEX NAME)



RN 676495-03-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[[3-(2-methyl-1-piperidinyl)propyl]amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676495-06-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(pentylamino)methyl]phenoxy]- (CA INDEX

NAME)



RN 676495-11-7 CAPLUS
CN Benzamide, 4-[4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)



RN 676495-42-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-ethoxy-4-[[(3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676494-41-0
CMF C20 H27 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676495-43-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(butylamino)methyl]-2-ethoxyphenoxy]- (CA INDEX NAME)



RN 676496-50-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[(3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676496-49-4
CMF C18 H23 N3 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676496-52-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-[2-methyl-4-[[(3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676496-51-8
CMF C19 H25 N3 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676496-55-2 CAPLUS
CN 2-Pyridinecarboxamide, 5-[2-methoxy-4-[[(3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676496-54-1
CMF C19 H25 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676496-80-3 CAPLUS
CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[(3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676496-79-0
CMF C18 H22 F N3 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676496-84-7 CAPLUS
CN Pyrazinecarboxamide, 5-[2-methyl-4-[[(3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676496-83-6
CMF C18 H24 N4 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676496-88-1 CAPLUS
CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)



RN 676496-93-8 CAPLUS
CN 2-Pyridinecarboxamide, 5-[2-chloro-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676496-96-1 CAPLUS
CN 2-Pyridinecarboxamide, 5-[2-chloro-4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)



RN 676496-99-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676497-06-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)



RN 676497-10-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(3,3-dimethylbutyl)amino]methyl]-2-methoxyphenoxy]- (CA INDEX NAME)



RN 676497-12-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(butylamino)methyl]-2-methoxyphenoxy]- (CA INDEX NAME)



RN 676497-18-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(hexylamino)methyl]-2-methoxyphenoxy]- (CA INDEX NAME)



RN 676497-20-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[(4-methylpentyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676497-19-1

CMF C20 H27 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676497-24-8 CAPLUS
CN Pyrazinecarboxamide, 5-[4-[[(3,3-dimethylbutyl)amino]methyl]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 676497-25-9 CAPLUS
CN Pyrazinecarboxamide, 5-[4-[[(3-methylbutyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 676497-29-3 CAPLUS
CN Pyrazinecarboxamide, 5-[4-[[(3,3-dimethylbutyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 676497-67-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[(3-methylbutyl)pentylamino]methyl]phenoxy]- (CA INDEX NAME)



RN 676497-68-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[(3-methylbutyl)propylamino]methyl]phenoxy]- (CA INDEX NAME)



RN 676497-69-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[bis(3-methylbutyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)



RN 676497-86-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-chloro-4-[[(3,3-dimethylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676498-03-6 CAPLUS
CN Benzamide, 4-[2-methyl-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676498-08-1 CAPLUS
CN Benzamide, 4-[3-chloro-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676498-13-8 CAPLUS
CN Benzamide, 4-[2-ethoxy-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676499-89-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(cyclopropylmethyl)(3-methylbutyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)





RN 676499-90-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(cyclohexylmethyl)(3-methylbutyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)



RN 676500-01-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[(propylamino)methyl]phenoxy]- (CA INDEX NAME)



RN 676500-02-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[(hexylamino)methyl]phenoxy]- (CA INDEX NAME)



RN 676500-23-5 CAPLUS
CN Benzamide, 4-[2-chloro-4-[[(3,3-dimethylbutyl)amino]methyl]phenoxy]- (CA

INDEX NAME)



RN 676500-24-6 CAPLUS
CN Benzamide, 4-[2-chloro-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676500-25-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(3-methylbutyl)amino]methyl]phenoxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 676500-26-8 CAPLUS
CN Benzamide, 4-[2-chloro-4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)



RN 676500-38-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2,3-difluoro-4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)



RN 676500-42-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(3,3-dimethylbutyl)amino]methyl]-2-fluoro-6-methoxyphenoxy]- (CA INDEX NAME)



RN 676500-45-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(3,3-dimethylbutyl)amino]methyl]-2,6-difluorophenoxy]- (CA INDEX NAME)



RN 676500-48-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2,6-difluoro-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676500-49-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2,3,6-trifluoro-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676500-65-5 CAPLUS
CN Pyrazinecarboxamide, 5-[2-methoxy-4-[(pentylamino)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 676500-73-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[(propylamino)methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-72-4
CMF C17 H21 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676500-81-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(heptylamino)methyl]-2-methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-80-4
CMF C21 H29 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676500-85-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[(3-methoxypropyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-84-8
CMF C18 H23 N3 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676500-87-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(3-ethoxypropyl)amino]methyl]-2-methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-86-0
CMF C19 H25 N3 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676500-89-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[3-(1-methylethoxy)propyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-88-2
CMF C20 H27 N3 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676500-93-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[(3-ethylpentyl)amino]methyl]-2-methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-92-8
CMF C21 H29 N3 O3



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676500-98-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[3-(4-morpholinyl)propyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-97-3
CMF C21 H28 N4 O4



CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676500-99-5 CAPLUS
CN Pyrazinecarboxamide, 5-[4-[[(3,3-dimethylbutyl)amino]methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 676501-05-6 CAPLUS
CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[(4-methylpentyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676501-06-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[(3,3-dimethylbutyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)



RN 676501-08-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[(3-ethylpentyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)



RN 676501-12-5 CAPLUS
CN Pyrazinecarboxamide, 5-[2-fluoro-4-[(pentylamino)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 676501-13-6 CAPLUS
CN Pyrazinecarboxamide, 5-[4-[[(4,4-dimethylpentyl)amino]methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 676501-14-7 CAPLUS
CN Pyrazinecarboxamide, 5-[4-[[(3-ethylpentyl)amino]methyl]-2-fluorophenoxy]- (9CI) (CA INDEX NAME)



RN 676501-19-2 CAPLUS
CN Pyrazinecarboxamide, 5-[2-fluoro-4-[(hexylamino)methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 676501-21-6 CAPLUS
CN Pyrazinecarboxamide, 5-[2-fluoro-4-[[[3-(1-methylethoxy)propyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 676501-32-9 CAPLUS
CN Pyrazinecarboxamide, 5-[2-methoxy-4-[[(3-methylbutyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 676501-33-0 CAPLUS
CN Pyrazinecarboxamide, 5-[2-methoxy-4-[[(4-methylpentyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 676501-34-1 CAPLUS
CN Pyrazinecarboxamide, 5-[4-[[(3,3-dimethylbutyl)amino]methyl]-2-methoxyphenoxy]- (9CI) (CA INDEX NAME)



RN 676501-35-2 CAPLUS
CN Pyrazinecarboxamide, 5-[4-[[(4,4-dimethylpentyl)amino]methyl]-2-methoxyphenoxy]- (9CI) (CA INDEX NAME)



RN 676501-36-3 CAPLUS
CN Pyrazinecarboxamide, 5-[4-[[(3-ethylpentyl)amino]methyl]-2-methoxyphenoxy]- (9CI) (CA INDEX NAME)



RN 676501-39-6 CAPLUS
CN Pyrazinecarboxamide, 5-[2-methoxy-4-[[(3-methoxypropyl)amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 676501-81-8 CAPLUS
CN Pyrazinecarboxamide, 5-[2-fluoro-4-[[(3-methylbutyl)amino]methyl]phenoxy]-
(9CI) (CA INDEX NAME)



RN 676501-82-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methyl-4-[[(3-methylbutyl)amino]methyl]phenoxy
]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676494-38-5
CMF C19 H25 N3 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=>
Connecting via Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 13:41:16 ON 26 DEC 2007
FILE 'CAPLUS' ENTERED AT 13:41:16 ON 26 DEC 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               25.68     199.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               -2.34      -2.34

=> file registry
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               25.68     199.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                               -2.34      -2.34

FILE 'REGISTRY' ENTERED AT 13:41:27 ON 26 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 DEC 2007  HIGHEST RN 959463-53-7
DICTIONARY FILE UPDATES:  25 DEC 2007  HIGHEST RN 959463-53-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10 series\10526960\10526960b.str
```





chain nodes :
7 16 17 18 19 20 21 22 23 24 27 28
ring nodes :
1 2 3 4 5 6 8 9 10 11 12 13
chain bonds :
1-24 2-28 3-16 5-27 6-7 7-8 11-21 16-17 17-18 18-19 19-20 21-22 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 8-9 8-13 9-10 10-11 11-12 12-13
exact/norm bonds :
1-24 2-28 3-16 5-27 6-7 7-8 8-9 8-13 9-10 10-11 11-12 11-21 12-13
16-17 17-18 18-19 19-20 21-22 21-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:N,CH

G2:X,O,CH3,H

G3:H,X

G4:H,X,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:CLASS
22:CLASS 23:CLASS 24:CLASS 27:CLASS 28:CLASS

L5 STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5 STR



G1 N,CH

G2 X,O,Me,H

G3 H,X

G4 H,X,O

Structure attributes must be viewed using STN Express query preparation.

=> s l5 full
FULL SEARCH INITIATED 13:41:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 23372 TO ITERATE

100.0% PROCESSED 23372 ITERATIONS 95 ANSWERS
SEARCH TIME: 00.00.01

L6 95 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	371.20
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

FILE 'CAPLUS' ENTERED AT 13:41:55 ON 26 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Dec 2007 VOL 147 ISS 26
FILE LAST UPDATED: 25 Dec 2007 (20071225/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l6
L7 3 L6

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.47	371.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.34

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:42:04 ON 26 DEC 2007